BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Receives Regulatory Approval for Phase II Ebola Trial of NV-387 Oral Gummies

NanoViricides, Inc. (NYSE American: NNVC) announced that it has received regulatory approval from the local regulatory agency “ACOREP” in the Democratic Republic of Congo (“DRC”) to begin a Phase II clinical trial of NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak and other Ebola viruses. The company has retained Om Sai Clinical Research Private […]